Sintilimab Plus Chemo With or Without IBI305 Provides PFS Benefit in EGFR TKI–Pretreated EGFR+ NSCLC

The combination of sintilimab and chemotherapy with or without the bevacizumab biosimilar IBI305 produced a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with EGFR-mutated, nonsquamous non–small cell lung cancer who progressed after treatment with an EGFR TKI.

Related Keywords

Shanghai ,China ,Rhui Zhou ,Guangdong , ,China National Medical Products Administration ,Oncology Department Of Shanghai Chest Hospital ,Lancet Respiratory Medicine ,Oncology Department ,Shanghai Chest Hospital ,National Medical Products Administration ,Lancet Oncology ,Lancet Respiratory ,Sintilimab ,Ibi305 ,Egfr Mutated Nsclc ,Non Small Cell Lung Cancer ,Nct03802240 ,Orient 31 Trial ,